1. Home
  2. ALLT vs IVVD Comparison

ALLT vs IVVD Comparison

Compare ALLT & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Allot Ltd.

ALLT

Allot Ltd.

HOLD

Current Price

$7.07

Market Cap

519.6M

ML Signal

HOLD

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$1.27

Market Cap

437.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALLT
IVVD
Founded
1996
2020
Country
Israel
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
519.6M
437.1M
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
ALLT
IVVD
Price
$7.07
$1.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$12.40
$8.75
AVG Volume (30 Days)
344.2K
2.6M
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
79.02
EPS
N/A
N/A
Revenue
N/A
$53,426,000.00
Revenue This Year
$15.84
$147.67
Revenue Next Year
$12.08
$22.76
P/E Ratio
$469.21
N/A
Revenue Growth
N/A
110.47
52 Week Low
$4.37
$0.46
52 Week High
$11.92
$3.07

Technical Indicators

Market Signals
Indicator
ALLT
IVVD
Relative Strength Index (RSI) 50.11 37.30
Support Level $6.20 $0.69
Resistance Level $8.20 $1.41
Average True Range (ATR) 0.29 0.13
MACD 0.17 -0.02
Stochastic Oscillator 100.00 16.28

Price Performance

Historical Comparison
ALLT
IVVD

About ALLT Allot Ltd.

Allot Ltd is a provider of network intelligence and security solutions for service providers and enterprises. The company's solutions are deployed globally for network and application analytics, traffic control and shaping, and network-based security services. The firm's multi-service platforms are deployed by mobile, fixed, and cloud service providers and enterprises. The company has a customer base in Europe, Asia and Oceania, the Americas, the Middle East, and Africa.

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: